Compare GH & FIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GH | FIG |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | 1886 |
| Industry | Medical Specialities | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 15.2B |
| IPO Year | 2018 | N/A |
| Metric | GH | FIG |
|---|---|---|
| Price | $85.12 | $23.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 12 |
| Target Price | ★ $117.80 | $50.50 |
| AVG Volume (30 Days) | 1.7M | ★ 14.4M |
| Earning Date | 04-29-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.74 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $982,021,000.00 | N/A |
| Revenue This Year | $33.40 | $31.18 |
| Revenue Next Year | $28.55 | $20.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.88 | N/A |
| 52 Week Low | $36.36 | $19.85 |
| 52 Week High | $120.74 | $114.29 |
| Indicator | GH | FIG |
|---|---|---|
| Relative Strength Index (RSI) | 34.90 | 38.04 |
| Support Level | $82.26 | $19.85 |
| Resistance Level | $103.16 | $25.17 |
| Average True Range (ATR) | 3.94 | 1.67 |
| MACD | 0.07 | -0.49 |
| Stochastic Oscillator | 20.02 | 6.52 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Figma Inc is engaged in transforming ideas into digital products and experiences. The group focuses on the entire software creation lifecycle, enabling it to quickly launch new products on Figma's browser-based platform and reinforcing its belief that design extends well beyond a single step or role. The company adopts an expansive view, as design is more than how something looks, feels, or works. It derives its revenue from sales of subscriptions for access to its platform.